Is Omeprazole Safe During Pregnancy? What the Evidence Says
TL;DR
- Omeprazole is the only proton pump inhibitor (PPI) classified as former FDA pregnancy category C — all other PPIs are category B — making it a less preferred first choice during pregnancy [4] [5].
- Gastroesophageal reflux disease (GERD) affects up to 80% of pregnant women; treatment should follow a step-up approach starting with lifestyle changes, then antacids, then H2-receptor antagonists, with PPIs reserved for severe or complicated cases [4] [5].
- If a PPI is truly needed, most guidelines recommend choosing a category B alternative such as lansoprazole or pantoprazole rather than omeprazole, although large-scale human data have not demonstrated a clear teratogenic signal for omeprazole [1] [4].
Why Omeprazole Comes Up So Often in Pregnancy
Heartburn and acid reflux are among the most common complaints of pregnancy. Declining lower oesophageal sphincter (LOS) pressure — driven primarily by rising progesterone levels — along with increased intra-abdominal pressure from the growing uterus, creates a perfect environment for gastric acid to escape into the oesophagus [5]. Gastroesophageal reflux disease in pregnancy affects up to 80% of women, with symptoms typically worsening as gestation progresses [4].
Omeprazole (Prilosec, Losec) is one of the most widely used and most familiar PPIs worldwide. It is available over the counter in many countries and is often the first acid-suppressing medication that patients — and some clinicians — reach for. The question of whether omeprazole is safe during pregnancy therefore arises frequently, and the answer is more nuanced than a simple yes or no.
PPIs as a class are considered extremely safe in the general population [6]. However, pregnancy adds a layer of complexity: any drug taken by the mother can potentially cross the placenta and affect the developing fetus, particularly during the first trimester when organogenesis is most active [2]. While the majority of pregnant women receive at least one medication during pregnancy, and approximately 6% take a drug during the high-risk first trimester [2], the guiding principle remains that medications should be avoided unless the benefit clearly outweighs the risk.
Omeprazole and the FDA Pregnancy Category System
To understand the controversy around omeprazole in pregnancy, it helps to review the old FDA pregnancy category framework that these classifications come from. Although the FDA replaced the letter-category system with the Pregnancy and Lactation Labeling Rule (PLLR) in 2015, the A/B/C/D/X designations remain widely referenced in clinical literature and prescribing discussions.
Category B means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate, well-controlled studies in pregnant women — or that animal studies have shown an adverse effect that was not confirmed in controlled human studies.
Category C means that animal reproduction studies have shown an adverse effect on the fetus, there are no adequate, well-controlled studies in humans, but the potential benefits may warrant use despite potential risks.
Omeprazole is the only PPI that carries the former FDA category C designation [4] [5]. All other PPIs — including esomeprazole, lansoprazole (Prevacid), pantoprazole (Protonix), and rabeprazole (AcipHex) — are classified as category B [4] [5]. This distinction is based primarily on older animal data: high-dose omeprazole administered to pregnant rabbits showed embryotoxicity and fetotoxicity, which prompted the more cautious classification.
It is worth noting that category C does not mean "contraindicated." It means the evidence base is less reassuring than for category B drugs, and therefore clinical judgment is needed. Several authoritative reviews have concluded that PPIs should be reserved for pregnant women with intractable symptoms or complicated reflux disease, and that when a PPI is required, alternatives to omeprazole are generally preferred [4] [5].
However, there is some nuance in the literature. At least one comprehensive review of long-term PPI safety has described omeprazole as "a safe choice of PPI" for severe GERD conditions in pregnancy, while simultaneously recommending lifestyle modifications and antacids as first-line treatment [1]. This likely reflects the fact that the large body of human exposure data accumulated over decades has not demonstrated a clear, consistent teratogenic signal for omeprazole.
Step-Up Treatment Algorithm for GERD in Pregnancy
Current guidelines recommend a graduated approach to managing heartburn and GERD during pregnancy [4] [5]. The table below outlines this step-up strategy.
| Step | Intervention | Recommendation Grade | Notes |
|---|---|---|---|
| 1 | Lifestyle and dietary modifications | First-line for all patients | Elevate head of bed, avoid late meals, reduce fatty/spicy foods, eat smaller and more frequent meals |
| 2 | Calcium-containing antacids or alginates | Grade A recommendation [4] | Avoid sodium bicarbonate (risk of metabolic alkalosis and fluid retention); avoid magnesium trisilicate at high doses near term |
| 3 | Sucralfate | Grade C recommendation [4] | Mucosal protectant; minimal systemic absorption; considered safe |
| 4 | H2-receptor antagonists (ranitidine*, famotidine, cimetidine) | Grade B recommendation [4] | All are considered safe except nizatidine [2] [5]. *Ranitidine was withdrawn from most markets in 2020 due to NDMA contamination — famotidine is the current preferred H2RA |
| 5 | Proton pump inhibitors | Reserved for intractable or complicated GERD [4] [5] | Prefer category B PPIs (lansoprazole, pantoprazole, esomeprazole). Omeprazole is category C — use only when no alternative is suitable |
This step-up approach is endorsed by multiple reviews and is reflected in guidelines from gastroenterology societies [4] [5] [6]. The rationale is straightforward: start with the safest and least systemic interventions, escalating only when symptoms remain uncontrolled.
Richter (2005) emphasised that serious reflux complications during pregnancy are rare, meaning that upper endoscopy and other invasive diagnostic tests are infrequently needed [5]. This further supports a conservative, stepwise approach to pharmacotherapy.
Omeprazole vs. Other PPIs: Efficacy and Safety Comparison
When a PPI is clinically necessary in pregnancy, clinicians often face the question of which agent to choose. The table below compares the most commonly used PPIs in terms of their pregnancy classification and clinical profile.
| PPI | Former FDA Category | Relative Potency (vs. omeprazole 20 mg) | Key Considerations in Pregnancy |
|---|---|---|---|
| Omeprazole 20 mg | C | Reference standard | Category C due to animal data; extensive human exposure data without clear teratogenic signal; not first-line in pregnancy [4] [5] |
| Esomeprazole 20–40 mg | B | Slightly superior at 40 mg dose [7] [8] | S-isomer of omeprazole; statistically higher healing rates at 40 mg vs. omeprazole 20 mg [8]; category B |
| Lansoprazole 15–30 mg | B | Comparable | Category B; commonly recommended as pregnancy-appropriate PPI |
| Pantoprazole 20–40 mg | B | Comparable | Category B; fewer drug interactions via CYP2C19 |
| Rabeprazole 20 mg | B | Comparable | Category B; less prescribing experience in pregnancy compared to lansoprazole or pantoprazole |
Esomeprazole deserves special mention because it is the S-isomer of omeprazole — essentially the pharmacologically active half of the racemic omeprazole molecule. A large randomised controlled trial demonstrated that esomeprazole 40 mg achieved significantly higher healing rates than omeprazole 20 mg in patients with erosive oesophagitis (93.7% vs. 84.2% at 8 weeks, p < 0.001) [8]. A subsequent meta-analysis confirmed a statistically significant advantage for esomeprazole over omeprazole in GERD healing (RR = 1.06, 95% CI 1.01–1.10), though tolerability was similar between the two agents [7].
The clinical implication for pregnancy is notable: if a pregnant woman requires a PPI and has previously relied on omeprazole, esomeprazole offers a closely related pharmacological profile with the advantage of a category B classification. This makes it a logical alternative in many cases.
Adverse Effects and Safety Concerns with PPIs in Pregnancy
All PPIs share a common mechanism — irreversible inhibition of the gastric hydrogen-potassium ATPase (the "proton pump") — and therefore share a similar adverse-effect profile. The table below summarises key safety concerns relevant to PPI use during pregnancy.
| Adverse Effect | Frequency / Risk Level | Recommended Action |
|---|---|---|
| Nausea, headache, diarrhoea | Common (reported in clinical trials) [8] | Usually mild and self-limiting; monitor and reassure |
| Vitamin B12 deficiency | Risk increases with long-term use [1] | Relevant mainly for chronic users; monitor if PPI used throughout pregnancy |
| Iron deficiency | Risk with prolonged acid suppression [1] | Gastric acid is needed for iron absorption; supplement if indicated, especially given pregnancy-related iron demands |
| Calcium and magnesium malabsorption | Risk with long-term use [1] | Monitor serum magnesium if prolonged use; ensure adequate calcium intake for fetal skeletal development |
| Vitamin C reduction | Reported with chronic use [1] | Ensure dietary intake is adequate |
| Enteric infections (e.g., Clostridioides difficile) | Increased risk with acid suppression [1] | Use lowest effective dose for shortest duration |
| Respiratory and urinary tract infections | Reported association with chronic PPI use [1] | Clinical relevance in short-term pregnancy use is uncertain |
| Hypergastrinaemia, gastric polyps | Long-term risk [1] | Not typically relevant for time-limited pregnancy use |
| Potential congenital malformations | Discussed in literature; no consistent signal in large studies [1] | Use PPIs only when clearly needed; prefer category B agents; avoid first trimester if possible |
A key review by Koyyada (2021) highlighted that long-term PPI use by pregnant patients "may impose a potential risk of congenital malformations," while also noting that various studies have recommended preserving PPIs for severe conditions, with omeprazole acknowledged as a relatively safe PPI choice when one is required [1]. This apparent contradiction reflects the broader state of the evidence: animal data raise theoretical concerns, but large-scale human observational studies have generally not confirmed a meaningful increase in birth defects with omeprazole exposure.
The practical takeaway is that short-course PPI therapy for refractory GERD in the second or third trimester carries a low absolute risk, but first-trimester exposure warrants greater caution due to the theoretical vulnerability during organogenesis.
Clinical Pearls and Special Populations
First Trimester Considerations
The first trimester is the period of greatest concern for any medication exposure. Organ formation occurs primarily between weeks 3 and 8 of gestation, and drug-induced teratogenicity is most likely during this window. Several sources in the pregnancy pharmacotherapy literature recommend avoiding PPIs during the first trimester when possible [2] [3]. If acid suppression is required in early pregnancy, H2-receptor antagonists (particularly famotidine) are generally the preferred step before reaching for a PPI [4] [5].
Patients Already Taking Omeprazole at Conception
Women who discover they are pregnant while taking omeprazole should not panic. The available human data do not support a strong teratogenic risk. However, it is prudent to discuss the finding with a prescriber as soon as possible. Options include:
- Discontinuing the PPI and trialling lifestyle modifications plus antacids
- Stepping down to an H2-receptor antagonist
- Switching to a category B PPI (e.g., lansoprazole, pantoprazole, or esomeprazole) if continued acid suppression is truly necessary
Lactation
Most systemic acid-suppressing drugs are excreted in breast milk. Among the options, H2-receptor antagonists (with the exception of nizatidine) are considered safe during lactation [5]. Data on PPI excretion in breast milk are more limited, and the clinical significance of any exposure to the nursing infant is not fully established. Omeprazole is detectable in breast milk at low concentrations; whether this has any clinical effect on the infant is unknown. [VERIFY]
Complicated GERD and Barrett's Oesophagus
In the rare case of a pregnant woman with complicated GERD — stricture, severe erosive oesophagitis, or Barrett's oesophagus — PPI therapy may be genuinely necessary regardless of pregnancy category [5] [6]. In these situations, the risk of untreated disease (aspiration, malnutrition, oesophageal injury) may outweigh theoretical drug risks. The decision should be made jointly with a gastroenterologist and obstetrician, and the lowest effective PPI dose should be used.
Conflicting Guidance Across Sources
It is worth acknowledging that the literature is not entirely uniform. Some ENT-focused reviews list PPIs as acceptable in pregnancy "except omeprazole" [2] [3], while gastroenterology-focused reviews describe omeprazole as an option — albeit a less preferred one — for severe GERD [1] [5]. This discrepancy largely reflects the FDA category C designation and its interpretation by different specialty authors. The conservative approach — preferring category B PPIs when a PPI is required — represents the safest middle ground and is the recommendation adopted by most recent reviews [4].
Drug Interactions
Omeprazole is a moderate inhibitor of CYP2C19, which means it can interact with other medications metabolised through this pathway. In pregnancy, this is most relevant if the patient is also taking:
- Clopidogrel (antiplatelet therapy) — PPIs, especially omeprazole, may reduce clopidogrel efficacy [1]
- Certain antiepileptic drugs (phenytoin, diazepam)
- Some antidepressants (citalopram, escitalopram)
If a pregnant patient requires both a PPI and a CYP2C19-sensitive medication, pantoprazole — which has a lower interaction potential — may be the better choice.
FAQ
Q1: Can I take omeprazole in the first trimester of pregnancy? A1: Omeprazole is classified as former FDA category C, meaning animal studies showed some adverse effects and there are no adequate controlled studies in pregnant women. Most guidelines recommend avoiding PPIs — and omeprazole in particular — during the first trimester unless absolutely necessary [4] [5]. If you need acid suppression in early pregnancy, your doctor will likely try antacids or an H2-receptor antagonist (such as famotidine) first.
Q2: Is there a safer PPI than omeprazole for pregnancy? A2: Yes. Lansoprazole, pantoprazole, rabeprazole, and esomeprazole are all classified as former FDA category B, indicating a more reassuring safety profile in animal studies [4] [5]. Esomeprazole is particularly relevant because it is the active S-isomer of omeprazole and has similar efficacy [7] [8]. If you need a PPI during pregnancy, your prescriber will likely recommend one of these alternatives.
Q3: I was taking omeprazole before I knew I was pregnant. Should I be worried? A3: Brief inadvertent exposure to omeprazole in early pregnancy has not been linked to a clearly increased risk of birth defects in large observational studies. While omeprazole's category C label is based on high-dose animal data, the weight of human evidence is relatively reassuring [1]. Nonetheless, you should inform your healthcare provider so they can review your medication and decide whether to continue, switch, or stop the PPI.
Q4: Why is omeprazole category C when esomeprazole is category B? A4: This discrepancy relates to the timing and nature of the animal studies submitted for regulatory approval. Omeprazole's original preclinical data, conducted decades ago, showed embryotoxicity at high doses in rabbits. Esomeprazole, approved later, had more favourable animal reproductive data. Although the two drugs are closely related chemically (esomeprazole is the S-enantiomer of omeprazole), their regulatory files — and therefore their pregnancy categories — differ [4] [5].
Q5: Can I take omeprazole while breastfeeding? A5: Omeprazole is excreted in breast milk in small amounts. The clinical significance for the nursing infant is uncertain. H2-receptor antagonists (except nizatidine) are considered safer options during lactation [5]. If you require ongoing acid suppression while breastfeeding, discuss the options with your healthcare provider to choose the most appropriate agent.
References
[1] Koyyada A. Therapie (2021). PMID:32718584. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations
[2] Vlastarakos PV, Manolopoulos L, Ferekidis E. European Archives of Oto-Rhino-Laryngology (2008). PMID:18265995. Treating common problems of the nose and throat in pregnancy: what is safe?
[3] Vlastarakos PV, Nikolopoulos TP, Manolopoulos L. European Archives of Oto-Rhino-Laryngology (2008). PMID:18034353. Treating common ear problems in pregnancy: what is safe?
[4] Ortiz-Olvera N, Ochoa-Maya JP, González-Martínez MA. Gaceta Médica de México (2025). PMID:40743550. Gastroesophageal reflux disease and pregnancy: recommendations for safe treatment
[5] Richter JE. Alimentary Pharmacology & Therapeutics (2005). PMID:16225482. Review article: the management of heartburn in pregnancy
[6] Ramakrishnan A, Katz PO. Current Gastroenterology Reports (2002). PMID:12010622. Pharmacologic management of gastroesophageal reflux disease
[7] Qi Q, Wang R, Liu L. International Journal of Clinical Pharmacology and Therapeutics (2015). PMID:26329348. Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: a systematic review and meta-analysis
[8] Richter JE, Kahrilas PJ, Johanson J. The American Journal of Gastroenterology (2001). PMID:11280530. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial
About the author
Dr. Stanislav Ozarchuk, PharmD, has 15 years of clinical pharmacy experience. He writes for PillsCard.com, the international drug encyclopedia.
Medical disclaimer
The information provided here is for educational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.